> Detailanzeige

Roca, José-María; Alonso, Vicente; Pericay, Carles; Escudero, Pilar; Salud, Antonieta; Losa, Ferrán; López, Luis-Jesús; Guasch, Imma; Méndez, Miguel; Quintero-Aldana, Guillermo; Grande, Carlos; Vicente, Pilar; Arrivi, Antonio; Martin, Cristina; Moreno, Isabel; García, Pilar; Antón, Isabel; Constenla, Manuel; Yubero, Alfonso; Cirera, Luis

Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer
  • Beteiligte: Roca, José-María; Alonso, Vicente; Pericay, Carles; Escudero, Pilar; Salud, Antonieta; Losa, Ferrán; López, Luis-Jesús; Guasch, Imma; Méndez, Miguel; Quintero-Aldana, Guillermo; Grande, Carlos; Vicente, Pilar; Arrivi, Antonio; Martin, Cristina; Moreno, Isabel; García, Pilar; Antón, Isabel; Constenla, Manuel; Yubero, Alfonso; Cirera, Luis
  • Erschienen: S. Karger AG, 2010
  • Erschienen in: Chemotherapy
  • Sprache: Englisch
  • DOI: 10.1159/000313527
  • ISSN: 0009-3157; 1421-9794
  • Schlagwörter: Infectious Diseases ; Pharmacology (medical) ; Drug Discovery ; Pharmacology ; Oncology ; General Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>&lt;i&gt;Background:&lt;/i&gt; We gathered data from multiple institutions on the cetuximab regimen of patients with metastatic colorectal cancer. &lt;i&gt;Methods:&lt;/i&gt; 126 patients from 19 centers were included from July 2006 to July 2007 in this prospective non-controlled study. Irinotecan-refractory metastatic colorectal cancer patients with Karnofsky ≧70 received cetuximab 500 mg/m&lt;sup&gt;2&lt;/sup&gt; every 2 weeks (q2w) in combination with irinotecan 180 mg/m&lt;sup&gt;2&lt;/sup&gt; q2w until disease progression or unacceptable toxicity. The primary endpoint was the progression-free rate at 12 weeks. &lt;i&gt;Results:&lt;/i&gt; Median age was 65 years; 65.9% male; colon/rectum 64.3/34.1%; Karnofsky status ≤80/≧90% in 45.3/54.7% of the patients. The progression-free rate was 42.7 (95% CI 32.8–52.6) and 22.4% (95% CI 14.2–30.7) at 12 and 24 weeks, respectively. The main grade 3 or 4 toxicities were: diarrhea 13.5% and acne-like rash 10.3%. No grade 3 or 4 infusional or allergic reactions were reported. &lt;i&gt;Conclusions:&lt;/i&gt; The progression-free rates confirm that cetuximab q2w in combination with irinotecan is an option, and is as active and safe as the standard weekly regimen.</jats:p>